Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Menactra vs Menjugate in Infants
NCT01359449Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2011
- Primary completion
- Jul 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Serum Bactericidal Antibody (Baby Rabbit Complement) and Percentage of Participants with SBA-BR Titer >= 1:8. Started May 2011; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01359449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359449.